» Articles » PMID: 26632671

A Novel Intranuclear RNA Vector System for Long-term Stem Cell Modification

Overview
Journal Gene Ther
Date 2015 Dec 4
PMID 26632671
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Genetically modified stem and progenitor cells have emerged as a promising regenerative platform in the treatment of genetic and degenerative disorders, highlighted by their successful therapeutic use in inherent immunodeficiencies. However, biosafety concerns over insertional mutagenesis resulting from integrating recombinant viral vectors have overshadowed the widespread clinical applications of genetically modified stem cells. Here, we report an RNA-based episomal vector system, amenable for long-term transgene expression in stem cells. Specifically, we used a unique intranuclear RNA virus, borna disease virus (BDV), as the gene transfer vehicle, capable of persistent infections in various cell types. BDV-based vectors allowed for long-term transgene expression in mesenchymal stem cells (MSCs) without affecting cellular morphology, cell surface CD105 expression or the adipogenicity of MSCs. Similarly, replication-defective BDV vectors achieved long-term transduction of human induced pluripotent stem cells, while maintaining the ability to differentiate into three embryonic germ layers. Thus, the BDV-based vectors offer a genomic modification-free, episomal RNA delivery system for sustained stem cell transduction.

Citing Articles

Development of an RNA virus-based episomal vector with artificial aptazyme for gene silencing.

Komorizono R, Yoshizumi S, Tomonaga K Appl Microbiol Biotechnol. 2024; 108(1):491.

PMID: 39422780 PMC: 11489216. DOI: 10.1007/s00253-024-13327-8.


Viral Replicon Systems and Their Biosafety Aspects.

van der Meulen K, Smets G, Rudelsheim P Appl Biosaf. 2023; 28(2):102-122.

PMID: 37342518 PMC: 10278005. DOI: 10.1089/apb.2022.0037.


Reverse Genetics and Artificial Replication Systems of Borna Disease Virus 1.

Kanda T, Tomonaga K Viruses. 2022; 14(10).

PMID: 36298790 PMC: 9612284. DOI: 10.3390/v14102236.


The Borna Disease Virus 2 (BoDV-2) Nucleoprotein Is a Conspecific Protein That Enhances BoDV-1 RNA-Dependent RNA Polymerase Activity.

Kanda T, Horie M, Komatsu Y, Tomonaga K J Virol. 2021; 95(21):e0093621.

PMID: 34406860 PMC: 8513480. DOI: 10.1128/JVI.00936-21.


Optimal Expression of the Envelope Glycoprotein of Orthobornaviruses Determines the Production of Mature Virus Particles.

Sakai M, Fujita Y, Komorizono R, Kanda T, Komatsu Y, Noda T J Virol. 2020; 95(5).

PMID: 33268525 PMC: 8092845. DOI: 10.1128/JVI.02221-20.


References
1.
Urnov F, Miller J, Lee Y, Beausejour C, Rock J, Augustus S . Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature. 2005; 435(7042):646-51. DOI: 10.1038/nature03556. View

2.
Gaspar H, Parsley K, Howe S, King D, Gilmour K, Sinclair J . Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet. 2004; 364(9452):2181-7. DOI: 10.1016/S0140-6736(04)17590-9. View

3.
Yanai H, Hayashi Y, Watanabe Y, Ohtaki N, Kobayashi T, Nozaki Y . Development of a novel Borna disease virus reverse genetics system using RNA polymerase II promoter and SV40 nuclear import signal. Microbes Infect. 2006; 8(6):1522-9. DOI: 10.1016/j.micinf.2006.01.010. View

4.
Schneider U, Ackermann A, Staeheli P . A Borna disease virus vector for expression of foreign genes in neurons of rodents. J Virol. 2007; 81(13):7293-6. PMC: 1933307. DOI: 10.1128/JVI.02467-06. View

5.
Chinen J, Davis J, de Ravin S, Hay B, Hsu A, Linton G . Gene therapy improves immune function in preadolescents with X-linked severe combined immunodeficiency. Blood. 2007; 110(1):67-73. PMC: 1896128. DOI: 10.1182/blood-2006-11-058933. View